Christos Kyratsous, PhD, is the Vice President of Research, Infectious Disease and Viral Vector Technologies at Regeneron. In his role, he oversees preclinical research into a diverse portfolio of anti-pathogen fully-human monoclonal antibodies and novel gene and cell therapies. His team utilizes Regeneron’s key ‘rapid response’ technologies, including the company's proprietary VelocImmune® mice with genetically-modified human immune systems, to dramatically accelerate the drug discovery and development process. Throughout his nine-year tenure at the company, Dr. Kyratsous has made a significant impact on global health, including leading the development of REGN-EB3, a drug candidate for the treatment of Ebola, and most recently, leading Regeneron’s efforts to develop novel antibodies against COVID-19. Prior to joining the Regeneron team in 2011, Dr. Kyratsous conducted his postdoctoral fellowship in Molecular Biology at New York University. He earned his BS in Pharmaceutical Sciences from Aristotle University of Thessaloniki in Greece, and received his MPhil, MA and PhD in Microbiology from Columbia University.